Enanta Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Enanta Pharmaceuticals CEO'su Jay Luly, Jul2003 tarihinde atandı, in görev süresi 21.33 yıldır. in toplam yıllık tazminatı $ 7.86M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.6% maaş ve 90.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.51% ine doğrudan sahiptir ve bu hisseler $ 6.57M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 8 yıldır.
Anahtar bilgiler
Jay Luly
İcra Kurulu Başkanı
US$7.9m
Toplam tazminat
| CEO maaş yüzdesi | 9.6% |
| CEO görev süresi | 21.3yrs |
| CEO sahipliği | 3.5% |
| Yönetim ortalama görev süresi | 3.9yrs |
| Yönetim Kurulu ortalama görev süresi | 8yrs |
Son yönetim güncellemeleri
Recent updates
Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet
Nov 27
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Oct 05Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 24Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$116m |
| Jun 30 2024 | n/a | n/a | -US$115m |
| Mar 31 2024 | n/a | n/a | -US$132m |
| Dec 31 2023 | n/a | n/a | -US$138m |
| Sep 30 2023 | US$8m | US$755k | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$125m |
| Dec 31 2022 | n/a | n/a | -US$121m |
| Sep 30 2022 | US$7m | US$725k | -US$122m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$101m |
| Sep 30 2021 | US$5m | US$693k | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | n/a | n/a | -US$58m |
| Sep 30 2020 | US$5m | US$667k | -US$36m |
| Jun 30 2020 | n/a | n/a | US$2m |
| Mar 31 2020 | n/a | n/a | US$24m |
| Dec 31 2019 | n/a | n/a | US$34m |
| Sep 30 2019 | US$4m | US$642k | US$46m |
| Jun 30 2019 | n/a | n/a | US$65m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | n/a | n/a | US$86m |
| Sep 30 2018 | US$4m | US$611k | US$72m |
Tazminat ve Piyasa: Jay 'nin toplam tazminatı ($USD 7.86M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.45M ).
Tazminat ve Kazançlar: Jay şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Jay Luly (68 yo)
21.3yrs
Görev süresi
US$7,856,698
Tazminat
Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer, President and Director of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxfor...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 21.3yrs | US$7.86m | 3.51% $ 6.6m | |
| Chief Financial & Administrative Officer | 21.2yrs | US$2.85m | 0.35% $ 660.9k | |
| Senior VP of Research & Development and Chief Scientific Officer | 25yrs | US$2.97m | 1.66% $ 3.1m | |
| Consultant | less than a year | US$2.86m | 0.43% $ 799.7k | |
| Chief Business Officer | 3.8yrs | US$2.58m | 0.10% $ 192.6k | |
| Senior Director of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok | |
| Chief Legal Officer | less than a year | Veri yok | Veri yok | |
| Chief Product Strategy Officer | 3.9yrs | US$2.10m | 0.071% $ 133.0k | |
| Senior VP & Chief Medical Officer | 2.3yrs | US$4.84m | 0.017% $ 31.2k |
3.9yrs
Ortalama Görev Süresi
59.5yo
Ortalama Yaş
Deneyimli Yönetim: ENTA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 21.3yrs | US$7.86m | 3.51% $ 6.6m | |
| Independent Director | 4.4yrs | US$331.41k | 0% $ 0 | |
| Independent Non-Executive Chairman | 11yrs | US$353.91k | 0% $ 0 | |
| Independent Director | 13.4yrs | US$333.91k | 0.027% $ 51.2k | |
| Independent Director | 7.2yrs | US$326.41k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$318.91k | 0% $ 0 | |
| Independent Director | 8yrs | US$321.41k | 0% $ 0 |
8.0yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ENTA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8 yıldır).